John Pearson
Nurse Practitioner · Camden, DENPI 1962400655
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 440 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 440 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$972
- AbbVie$822
- Lilly USA, LLC$645
- GSK$605
- Biohaven Pharmaceuticals, Inc.$345
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,91299%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $1,426 |
| Novo Nordisk | 70 | $972 |
| AbbVie | 65 | $822 |
| Lilly USA, LLC | 38 | $645 |
| GSK | 36 | $605 |
| Biohaven Pharmaceuticals, Inc. | 30 | $345 |
| Pfizer | 30 | $321 |
| Biohaven Pharmaceutical Holding Company Ltd. | 24 | $279 |
| Abbott | 11 | $226 |
| Dexcom, Inc. | 11 | $211 |
| Boehringer Ingelheim | 11 | $172 |
| Astellas Pharma US Inc | 7 | $162 |
| Amgen | 8 | $133 |
| Exact Sciences | 5 | $96 |
| Phathom Pharmaceuticals, Inc. | 7 | $93 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $84 |
| Genentech USA, Inc. | 4 | $78 |
| Shield Therapeutics Inc | 2 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Optinose US, Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $19 |
| Novartis | 1 | $15 |
| Alkermes, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,982 in reported general payments places this provider in the 95th percentile of 487 nurse practitioner providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 88 | $158,443 |
| JardianceEmpagliflozin | 101 | $122,569 |
| OzempicSemaglutide | 46 | $88,173 |
| FarxigaDapagliflozin Propanediol | 62 | $77,532 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $55,563 |
| TrulicityDulaglutide | 26 | $48,055 |
| EliquisApixaban | 33 | $41,287 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $27,698 |
| JanuviaSitagliptin Phosphate | 19 | $26,346 |
| MovantikNaloxegol Oxalate | 18 | $7,240 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $6,714 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,699 |
| Atorvastatin Calcium | 525 | $5,906 |
| FenofibrateFenofibrate Nanocrystallized | 104 | $4,481 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 184 | $4,473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $645 | $206,498114 claims |
| Boehringer IngelheimJardiance | $172 | $122,569101 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,426 | $111,944130 claims |
| Novo NordiskOzempic | $972 | $88,17346 claims |
| GSKTrelegy Ellipta | $605 | $55,56360 claims |
| PfizerEliquis | $321 | $41,28733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 487 nurse practitioner providers in Delaware.
Other nurse practitioner in Camden
- Meghan McCarterSeaford$170K
- Chandni PatelMiddletown$113K
- Craig LaingMilford$51K
- Colleen DitroWilmington$16K
- Sedelle Henderson-BamideleNewark$13K
- Jennifer HubbardWilmington$12K
- Kathleen HudsonMillville$10K
- Nancy Townsend O'DayMillsboro$8K
- Funmilola OlaoyeNewark$7K
- Monica SamWilmington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.